HIGHLIGHTS
- who: Yan Li from the Faculty of Medicine and Psychology, Sapienza University of Rome, Italy have published the paper: Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report, in the Journal: (JOURNAL)
- what: The authors report a LUAD patient with heterogeneity of resistant mechanisms to EGFR-TKIs, mainly based on EGFR amplification, who was successfully treated with a combination treatment containing nimotuzumab and EGFR-TKIs subsequently.
- future: Studies are needed to effectively evaluate the efficacy of immunotherapy for NSCLC individuals with EGFR . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.